ENTX Entera Bio Ltd revenue, earnings and financials

For the quarter ended June 30, 2026, Entera Bio Ltd reported revenue of $0, net income of −$7.31M and diluted EPS of $0.14; over the last four quarters revenue was $0 and net income −$17.0M; for the fiscal year ended December 2025 revenue was $42.0K, down 76.8% on the year before.

ENTX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $42.0K, gross profit $0, operating income −$11.5M, net income −$11.4M (margin -27235.7%), EPS $0.25
• Fiscal year ended Dec 2024: revenue $181K, gross profit $9.00K, operating income −$9.59M, net income −$9.54M (margin -5271.3%), EPS $0.25
• Fiscal year ended Dec 2023: revenue $0, gross profit $0, operating income −$8.89M, net income −$8.89M (margin n/a), EPS $0.31
• Fiscal year ended Dec 2022: revenue $134K, gross profit $33.0K, operating income −$13.0M, net income −$13.1M (margin -9754.5%), EPS $0.45
• Fiscal year ended Dec 2021: revenue $571K, gross profit $198K, operating income −$12.2M, net income −$12.2M (margin -2134.3%), EPS $0.47

ENTX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $0, net income −$7.31M, EPS $0.14
• Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$3.51M, EPS $0.07
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0 (down 100.0% year over year), net income −$3.02M, EPS $0.06
• Quarter ended Sep 30, 2025: revenue $0 (down 100.0% year over year), net income −$3.20M, EPS $0.07
• Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$2.66M, EPS $0.06
• Quarter ended Mar 31, 2025: revenue $42.0K, net income −$2.57M, EPS $0.06
• Quarter ended Dec 31, 2024 (from the annual report): revenue $82.0K, net income −$2.36M, EPS $0.06
• Quarter ended Sep 30, 2024: revenue $42.0K, net income −$3.02M, EPS $0.08
• Quarter ended Jun 30, 2024: revenue $57.0K, net income −$2.15M, EPS $0.06
• Quarter ended Mar 31, 2024: revenue $0, net income −$2.02M, EPS $0.05
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0 (down 100.0% year over year), net income −$2.00M, EPS $0.07
• Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$2.38M, EPS $0.08
• Quarter ended Jun 30, 2023: revenue $0 (down 100.0% year over year), net income −$2.33M, EPS $0.08
• Quarter ended Mar 31, 2023: revenue $0 (down 100.0% year over year), net income −$2.19M, EPS $0.08
• Quarter ended Dec 31, 2022 (from the annual report): revenue $14.0K (down 91.5% year over year), net income −$3.04M, EPS $0.10
• Quarter ended Sep 30, 2022: revenue $8.00K (down 94.3% year over year), net income −$3.07M, EPS $0.11
• Quarter ended Jun 30, 2022: revenue $44.0K (down 59.6% year over year), net income −$3.19M, EPS $0.11
• Quarter ended Mar 31, 2022: revenue $68.0K (down 56.7% year over year), net income −$3.78M, EPS $0.13
• Quarter ended Dec 31, 2021 (from the annual report): revenue $165K, net income −$4.10M, EPS $0.16
• Quarter ended Sep 30, 2021: revenue $140K, net income −$3.21M, EPS $0.11

ENTX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$7.37M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$6.82M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$7.31M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$12.5M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$9.06M, share buybacks n/a

ENTX balance sheet

• Jun 30, 2026: cash $11.3M, total assets $19.5M, total liabilities $12.2M, shareholders' equity $7.27M
• Mar 31, 2026: cash $4.14M, total assets $13.1M, total liabilities $2.44M, shareholders' equity $10.7M
• Dec 31, 2025: cash $7.11M, total assets $16.0M, total liabilities $2.89M, shareholders' equity $13.1M
• Sep 30, 2025: cash $8.57M, total assets $17.4M, total liabilities $2.17M, shareholders' equity $15.2M
• Jun 30, 2025: cash $10.9M, total assets $19.7M, total liabilities $2.41M, shareholders' equity $17.3M
• Mar 31, 2025: cash $12.6M, total assets $21.6M, total liabilities $2.22M, shareholders' equity $19.4M
• Dec 31, 2024: cash $8.66M, total assets $9.39M, total liabilities $1.31M, shareholders' equity $8.08M
• Sep 30, 2024: cash $6.92M, total assets $7.74M, total liabilities $1.29M, shareholders' equity $6.45M

What is ENTX's revenue?

Entera Bio Ltd reported $0 of revenue over its last four quarters, through June 30, 2026.

Is ENTX profitable?

No. Entera Bio Ltd lost $17.0M over the last four quarters.

What is ENTX's EPS?

Diluted earnings per share over the last four quarters were $0.34; $0.14 in the latest quarter.

ENTX ownership and insider trades · All stocks